Press Releases
Alzheon Scientists Discover Endogenous Substance in Human Brain that Inhibits Formation of Toxic Beta Amyloid Oligomers, Key Driver of Alzheimer’s Disease
Publication Details Discovery of 3-Sulfopropanoic Acid, the Primary Metabolite of Tramiprosate and its Prodrug ALZ-801, in Cerebrospinal Fluid of Healthy Subjects as well as Alzheimer’s Patients [...]
Alzheon Appoints Former IVAX President, Neil Flanzraich, JD, as Vice Chairman of Board of Directors
Framingham, Mass. – August 6, 2018 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other [...]
Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease, Further Supporting Precision Medicine Approach and Planned Confirmatory Clinical Trial with ALZ-801
Presentation at the Alzheimer’s Association International Conference Details Patient Responder Analyses on Key Clinical Outcomes FRAMINGHAM, Mass., July 23, 2018 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused [...]
Alzheon to Make Presentations at Upcoming Industry and Investor Conferences
Keynote at Drug Discovery Innovation Programme and Company Presentation at JMP Securities Life Sciences ConferenceFRAMINGHAM, Mass., May 22, 2017 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused [...]
Alzheon Launches Roadshow for Initial Public Offering
FRAMINGHAM, Mass., April 2, 2018 – Alzheon, Inc. (“Alzheon”) announced today that it has launched the roadshow for the initial public offering of its common stock. [...]
Alzheon ALZ-801 Data Presented in Oral Session at CTAD on Role of Amyloid Oligomers in Alzheimer’s Disease
Therapeutic Inhibition of Toxic Beta Amyloid Oligomers Can Intervene Early in Amyloid Aggregation Cascade Two Additional Posters at CTAD Support Advancement of ALZ-801 to Phase 3 [...]